Report Preview

Chemotherapy-induced Thrombocytopenia Therapeutics Market

The global chemotherapy-induced thrombocytopenia therapeutics market size was valued at USD 1,550 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 5.0% in the forecasted period. The increasing incidence of cancer cases, growing research activities by the market players, rising number of chemotherapy procedures, and expanding acceptance of collaboration and acquisition approaches by the market players are amongst the major factors increasing the industry growth. Conversely, the deficiency of approved drugs for the treatment of chemotherapy-induced thrombocytopenia therapeutics are hampering the market from growth.

Rising prevalence of cancer and chemotherapy-induced thrombocytopenia around the world is anticipated to boost growth of the chemotherapy-induced thrombocytopenia therapeutics market during the forecasted period. For instance, as per the World Health Organization (WHO), cancer is one of the major cause of death globally, accounting for about 10 million deaths in 2020. Chemotherapy-induced thrombocytopenia (CIT) leads to postpone or decrease in cancer treatment. Moreover, as per the World Cancer Research Fund International’s report in 2018, lung cancer was graded at first position in the total number of cancer cases globally, totalling for 2,093,876 new lung cancer cases worldwide in 2018. Furthermore, as per the same source, breast cancer held for second position and new breast cancer cases reported worldwide in 2018 was around 2,088,849.

Furthermore, growing demand for thrombocytopenia treatment, rising number of pipeline products, and escalating awareness about thrombocytopenia and its treatment is estimated to boost the growth of the chemotherapy-induced thrombocytopenia therapeutics market. For example, in July 2019, Dova Pharmaceuticals broadcasted the launch of DOPTELET (avatrombopag) for treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an inadequate response to a former treatment. Similarly, in June 2019, Jiangsu HengRui Medicine Co., Ltd., initiated the Phase III study, to examine the efficiency and safety of Hetrombopag in patients with chemotherapy-induced thrombocytopenia getting chemotherapy for the treatment of solid tumors and lymphomas. The study is anticipated to complete in December 2020.

The outburst of COVID-19 has severely impacted the development, production, and supply of drugs of chemotherapy-induced thrombocytopenia. Also, pandemic has impacted each aspect of cancer care and research, as well as the delivery of cancer treatment. The effect of pandemic is more expected to occur in low and middle revenue nations with deficiency of health care providers, poor infrastructure, restricted resources, and poor access to technology causing in a lack of capability to provide critical care. This in turn is anticipated to hamper growth of the chemotherapy-induced thrombocytopenia therapeutics market.

Drug Class Insights

Based on the drug class, the global chemotherapy-induced thrombocytopenia therapeutics market is bifurcated into thrombopoietin receptor agonists, thrombopoietic agents, and others. The thrombopoietin receptor agonists segment is anticipated to boost the market growth in the estimated period. The factors affecting the market growth are increasing number of pipeline products for the treatment of chemotherapy-induced thrombocytopenia therapeutics. For instance, in October 2020, Institute of Hematology & Blood Diseases Hospital started the single-arm study to examine the safety and efficiency of eltrombopag to treat chemotherapy-induced thrombocytopenia. The investigation is under Phase II trial and is anticipated to finish by December 2023.

Region Insights

Among regions, North America, Europe, and Asia Pacific are expected to witness robust growth in the chemotherapy-induced thrombocytopenia therapeutics market due to the growing prevalence of cancer and chemotherapy-induced thrombocytopenia, rising research and development, growing number of pipeline products, and increasing awareness about thrombocytopenia and its treatment. For example, in March 2021, G1 Therapeutics, Inc. and Boehringer Ingelheim broadcasted that COSELA (trilaciclib) is now available in the U.S. The Food and Drug Administration (FDA) permitted COSELA in February 2021 to decline the incidence of chemotherapy-induced myelosuppression in adult patients. Chemotherapy-induced myelosuppression, can lead to augmented risk of infection, anemia, thrombocytopenia, and other problems.

Key Companies Insights

The market for chemotherapy-induced thrombocytopenia therapeutics is moderately competitive. With the rising applications of chemotherapy-induced thrombocytopenia therapeutics, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the chemotherapy-induced thrombocytopenia therapeutics market, ultimately boosting the market growth. Some of the key companies working in the global chemotherapy-induced thrombocytopenia therapeutics market include:

• Amgen Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Pfizer Inc.
• Janssen Global Services LLC
• Partner Therapeutics Inc.
• Mission Pharmacal Company
• Myelo Therapeutics GmbH
• Jiangsu HengRui Medicine Co. Ltd
• Dova Pharmaceuticals Inc.
• Other Players

Some of the Recent Developments:

• In October 2020, Sobi broadcasted topline results from its phase III study of avatrombopag, an oral thrombopoietin receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia.
• In September 2019, Amgen Inc., introduced Phase III trials, to study Romiplostim for chemotherapy-induced thrombocytopenia in adult with pancreatic, gastrointestinal, or colorectal cancer. The study is projected to complete in June 2023.

Segments

By Drug Class

• Thrombopoietin Receptor Agonists
• Thrombopoietic Agents
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • ASEAN
• Latin America
  • Brazil
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt